Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients.
Pfizer has been granted accelerated approval by the US FDA for their latest therapy for a certain type of blood cancer. The therapy, elranatamab, branded as Elrexfio, is now approved for use in patients with multiple myeloma, that is deemed especially hard to treat.
The therapy has been granted accelerated approval for it’s specific use where multiple myeloma patients have previously received a minimum of four treatment lines, including use of a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
This form of cancer, multiple myeloma, is a relatively common type of blood cancer, which initially develops in bone marrow and from there can spread throughout the body. Due to it’s capacity to spread easily through the body, patients who have been treated for the cancer often relapse when the initial treatment ceases. The recurrence of the cancer leaves patients open to undergoing several lines of treatment, prompting drug makers to address this ongoing issue.
The administration of elranatamab lends it to being more patient centric as it is delivered subcutaneously. The treatment is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, and works by assisting the body’s natural immune system by bringing the cancer cell into proximity of an immune cell.
10 Major Drug Approvals So Far in 2023
In this article we highlight 10 of the most recent novel drug approvals, covering a variety of fields of medicine, including migraines and menopause, to cancer drugs. Read the full article here >>>
The efficacy and safety of the treatment was evaluated in the clinical trial MagnetisMM-3 (NCT04649359), an open-label, single-arm, multi-centre study, consisting of 97 patients. The study looked at the objective response rate and the duration of response in these patients. Finding the response rate for the recommended dose was 57.7% and the duration of response at 6 months was 90.4% and at 9 months it was 82.3%.
Adverse side effects were seen in a large proportion of the test group, prompting the prescription information for elranatamab to come with a warning of life threatening or fatal cytokine release syndrome (CRS) and neurologic toxicity.
Pfizer will be selling the branded Elrexfio at a list price of around $41,500 per month, which is expected to drop as patients progress into bi-weekly dosing regimens. They project the peak revenue for the treatment could reach more than $4 billion.
Sources: Fierce Pharma. With FDA approval for Elrexfio, Pfizer brings multiple myeloma battle to Johnson & Johnson. [Date accessed 15/08/2023].
US Food and Drug Administration. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. [Date accessed 15/08/2023].
Related News
-
News Women in Pharma: Marketing for the other half in healthcare
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. This instalment highlights not only the importance of ma... -
News CAR-T therapy for renal cell carcinoma gains fast track approval
Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company. -
News CPHI Podcast Series: The ripple effects of nearshoring in pharma
In the most recent instalment of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenhage, President and CEO of PharmAdvice, to discuss nearshoring and reshoring in the pharmaceutical industry, and the subs... -
News Bringing the pharmaceutical supply chain closer to home
The pharmaceutical supply chain has encountered numerous disruptions in the last few years, impacting procurement, manufacturing, packaging, and distribution operations within the pharmaceutical industry. Read about the rise in calls for near/resh... -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News President Biden's executive order to increase access to contraception
In the USA, President Joe Biden will be signing an executive order to expand access to contraception. -
News CPHI North America 2023: from the experts – Sharp Services
Throughout CPHI North America (Philadelphia, PA; April 25–27, 2023), we caught up with some of the exhibiting organisations to ask what the show brings to the North American pharmaceutical sector, and what is driving industry innovation in this r...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance